CIDP and other inflammatory neuropathies in diabetes - Diagnosis and management

Yusuf A. Rajabally, Mark Stettner, Bernd C. Kieseier, Hans Peter Hartung, Rayaz Malik

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

Distal symmetric polyneuropathy (DSPN) is the most common neuropathy to occur in diabetes mellitus. However, patients with diabetes can also develop inflammatory neuropathies, the most common and most treatable of which is chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Whether diabetes is a risk factor for CIDP remains under debate. Early studies suggested that patients with diabetes were at increased risk of CIDP, but epidemiological studies failed to confirm the association, and subsequent data have re-opened the debate. Inadequate interpretation of investigations and differentials between CIDP and other neuropathies that can occur in diabetes, such as DSPN, diabetic radiculoplexus neuropathies and vasculitic multiple mononeuropathy, might mean that CIDP is under-recognized. Despite a response rate of >80% to first-line therapies for CIDP in patients with or without diabetes, those with diabetes often present with greater disability owing to late referral and axonal pathology attributed to DSPN. The increasing worldwide prevalence of diabetes creates an urgent need to improve identification of potentially treatable neuropathies, such as CIDP. In this Review, we consider the features of CIDP in patients with diabetes, and discuss how these features can be used to differentiate the condition from other neuropathies. We also review the management options for CIDP and other inflammatory neuropathies in patients with diabetes.

Original languageEnglish
Pages (from-to)599-611
Number of pages13
JournalNature Reviews Neurology
Volume13
Issue number10
DOIs
Publication statusPublished - 1 Oct 2017

Fingerprint

Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Polyneuropathies
Mononeuropathies
Diabetic Neuropathies
Epidemiologic Studies
Diabetes Mellitus
Referral and Consultation
Pathology

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this

CIDP and other inflammatory neuropathies in diabetes - Diagnosis and management. / Rajabally, Yusuf A.; Stettner, Mark; Kieseier, Bernd C.; Hartung, Hans Peter; Malik, Rayaz.

In: Nature Reviews Neurology, Vol. 13, No. 10, 01.10.2017, p. 599-611.

Research output: Contribution to journalReview article

Rajabally, Yusuf A. ; Stettner, Mark ; Kieseier, Bernd C. ; Hartung, Hans Peter ; Malik, Rayaz. / CIDP and other inflammatory neuropathies in diabetes - Diagnosis and management. In: Nature Reviews Neurology. 2017 ; Vol. 13, No. 10. pp. 599-611.
@article{3381c278735c4e9098aa256216f69c29,
title = "CIDP and other inflammatory neuropathies in diabetes - Diagnosis and management",
abstract = "Distal symmetric polyneuropathy (DSPN) is the most common neuropathy to occur in diabetes mellitus. However, patients with diabetes can also develop inflammatory neuropathies, the most common and most treatable of which is chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Whether diabetes is a risk factor for CIDP remains under debate. Early studies suggested that patients with diabetes were at increased risk of CIDP, but epidemiological studies failed to confirm the association, and subsequent data have re-opened the debate. Inadequate interpretation of investigations and differentials between CIDP and other neuropathies that can occur in diabetes, such as DSPN, diabetic radiculoplexus neuropathies and vasculitic multiple mononeuropathy, might mean that CIDP is under-recognized. Despite a response rate of >80{\%} to first-line therapies for CIDP in patients with or without diabetes, those with diabetes often present with greater disability owing to late referral and axonal pathology attributed to DSPN. The increasing worldwide prevalence of diabetes creates an urgent need to improve identification of potentially treatable neuropathies, such as CIDP. In this Review, we consider the features of CIDP in patients with diabetes, and discuss how these features can be used to differentiate the condition from other neuropathies. We also review the management options for CIDP and other inflammatory neuropathies in patients with diabetes.",
author = "Rajabally, {Yusuf A.} and Mark Stettner and Kieseier, {Bernd C.} and Hartung, {Hans Peter} and Rayaz Malik",
year = "2017",
month = "10",
day = "1",
doi = "10.1038/nrneurol.2017.123",
language = "English",
volume = "13",
pages = "599--611",
journal = "Nature Reviews Neurology",
issn = "1759-4758",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - CIDP and other inflammatory neuropathies in diabetes - Diagnosis and management

AU - Rajabally, Yusuf A.

AU - Stettner, Mark

AU - Kieseier, Bernd C.

AU - Hartung, Hans Peter

AU - Malik, Rayaz

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Distal symmetric polyneuropathy (DSPN) is the most common neuropathy to occur in diabetes mellitus. However, patients with diabetes can also develop inflammatory neuropathies, the most common and most treatable of which is chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Whether diabetes is a risk factor for CIDP remains under debate. Early studies suggested that patients with diabetes were at increased risk of CIDP, but epidemiological studies failed to confirm the association, and subsequent data have re-opened the debate. Inadequate interpretation of investigations and differentials between CIDP and other neuropathies that can occur in diabetes, such as DSPN, diabetic radiculoplexus neuropathies and vasculitic multiple mononeuropathy, might mean that CIDP is under-recognized. Despite a response rate of >80% to first-line therapies for CIDP in patients with or without diabetes, those with diabetes often present with greater disability owing to late referral and axonal pathology attributed to DSPN. The increasing worldwide prevalence of diabetes creates an urgent need to improve identification of potentially treatable neuropathies, such as CIDP. In this Review, we consider the features of CIDP in patients with diabetes, and discuss how these features can be used to differentiate the condition from other neuropathies. We also review the management options for CIDP and other inflammatory neuropathies in patients with diabetes.

AB - Distal symmetric polyneuropathy (DSPN) is the most common neuropathy to occur in diabetes mellitus. However, patients with diabetes can also develop inflammatory neuropathies, the most common and most treatable of which is chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Whether diabetes is a risk factor for CIDP remains under debate. Early studies suggested that patients with diabetes were at increased risk of CIDP, but epidemiological studies failed to confirm the association, and subsequent data have re-opened the debate. Inadequate interpretation of investigations and differentials between CIDP and other neuropathies that can occur in diabetes, such as DSPN, diabetic radiculoplexus neuropathies and vasculitic multiple mononeuropathy, might mean that CIDP is under-recognized. Despite a response rate of >80% to first-line therapies for CIDP in patients with or without diabetes, those with diabetes often present with greater disability owing to late referral and axonal pathology attributed to DSPN. The increasing worldwide prevalence of diabetes creates an urgent need to improve identification of potentially treatable neuropathies, such as CIDP. In this Review, we consider the features of CIDP in patients with diabetes, and discuss how these features can be used to differentiate the condition from other neuropathies. We also review the management options for CIDP and other inflammatory neuropathies in patients with diabetes.

UR - http://www.scopus.com/inward/record.url?scp=85032579184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032579184&partnerID=8YFLogxK

U2 - 10.1038/nrneurol.2017.123

DO - 10.1038/nrneurol.2017.123

M3 - Review article

VL - 13

SP - 599

EP - 611

JO - Nature Reviews Neurology

JF - Nature Reviews Neurology

SN - 1759-4758

IS - 10

ER -